Evidence map›Paper›PMID 37276436›Full record

ArticleScience immunology2023

Antibody-mediated immunity against lung cancer goes retro.

Stephanie N Langel, David R Martinez

Abstract readComment
PubMed Publisher
In one paragraph

Article in Science immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Stephanie N LangelDepartment of Pathology, Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0002-0467-7874
David R MartinezDepartment of Immunobiology, Yale Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-2940-8961

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endogenous retrovirus antibody responses contribute to survival after immune checkpoint blockade therapy against lung adenocarcinoma.

Indexed as

Lung NeoplasmsProgrammed Cell Death 1 ReceptorAntibodiesHumansAntibodiesProgrammed Cell Death 1 Receptor

Identifiers

PMID37276436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.